Wellness Research Center — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$1,001,983	6
2024	Research	$373,896	9
2023	Research	$77,831	10

Breakdown

Who paid Research payments · program years 2023–2025

E.R. Squibb & Sons, L.L.C. $717,228 5 payments
AstraZeneca Pharmaceuticals LP $661,248 5 payments
Sanofi US Services Inc. $75,024 12 payments
Sumitomo Pharma America, Inc. $210 3 payments

Studies the money was for Research payments · program years 2023–2025

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) $712,076 2 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $412,289 3 payments
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 $229,305 1 payment
A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naive People With Type 2 Diabetes Mellitus and Renal Impairment: TRENT Trial $75,024 12 payments
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $19,655 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) $2,603 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease $1,967 1 payment
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies $582 1 payment
A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication $140 2 payments
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication $70 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.